The stock of Apogee Therapeutics Inc (APGE) has seen a 8.63% increase in the past week, with a -1.52% drop in the past month, and a -12.30% decrease in the past quarter. The volatility ratio for the week is 4.69%, and the volatility levels for the past 30 days are at 6.34% for APGE. The simple moving average for the past 20 days is 4.65% for APGE’s stock, with a -0.54% simple moving average for the past 200 days.
Is It Worth Investing in Apogee Therapeutics Inc (NASDAQ: APGE) Right Now?
The stock has a 36-month beta value of 2.27. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APGE is 36.30M, and at present, short sellers hold a 21.96% of that float. On January 09, 2025, the average trading volume of APGE was 434.54K shares.
APGE) stock’s latest price update
The stock of Apogee Therapeutics Inc (NASDAQ: APGE) has decreased by -0.73 when compared to last closing price of 49.57.Despite this, the company has seen a gain of 8.63% in its stock price over the last five trading days. globenewswire.com reported 2024-12-02 that Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with Canaccord Genuity repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to Canaccord Genuity is $89 based on the research report published on November 25, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see APGE reach a price target of $80. The rating they have provided for APGE stocks is “Buy” according to the report published on May 10th, 2024.
BTIG Research gave a rating of “Buy” to APGE, setting the target price at $43 in the report published on December 20th of the previous year.
APGE Trading at -0.22% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.93% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 4.69%, as shares surge +0.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.55% lower at present.
During the last 5 trading sessions, APGE rose by +8.63%, which changed the moving average for the period of 200-days by -28.09% in comparison to the 20-day moving average, which settled at $47.02. In addition, Apogee Therapeutics Inc saw 8.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APGE starting from HENDERSON MICHAEL THOMAS, who proposed sale 15,000 shares at the price of $48.84 back on Jan 08 ’25. After this action, HENDERSON MICHAEL THOMAS now owns shares of Apogee Therapeutics Inc, valued at $732,675 using the latest closing price.
Dambkowski Carl, the Chief Medical Officer of Apogee Therapeutics Inc, sale 4,085 shares at $46.94 during a trade that took place back on Jan 02 ’25, which means that Dambkowski Carl is holding 255,348 shares at $191,740 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.24. Equity return is now at value -25.65, with -24.39 for asset returns.
Currently, EBITDA for the company is -83.98 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.39.
Conclusion
To sum up, Apogee Therapeutics Inc (APGE) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
